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1. LUNG CANCER SCREENING CHALLENGES. IS IMAGING SUFFICIENT 
FOR SUCCESSFUL SCREENING? THE UNMET NEEDS 
Current evidence supports screening of subjects who fit the NCI sponsored 
National Lung Screening Trial (NLST) criteria. The NLST compared annual low-
dose computed tomography (LDCT) screening with conventional chest 
radiography and found that LDCT screening achieved a 20% lung cancer 
mortality reduction after only three rounds of screening1. Prospective data 
accrued by the International Early Lung Cancer Action Program (iELCAP) from 
thousands of screening rounds, also support annual screening with LDCT 
(Henschke et al 2006), while data from the European NELSON trial, a Dutch-
Belgian initiative, are also favourable to screening2. Consequently, 
recommendations from prominent scientific societies support screening with 
LDCT despite concerns regarding false positive findings, the risk of 
overdiagnosis, logistical challenges, and differences in selection criteria3–6. 
Chief among these concerns is the widespread adoption of NLST age (55-74) 
and tobacco exposure (Pack-Years≥30) inclusion criteria by screening 
guidelines. Current evidence suggests that such criteria may preclude 
screening of many individuals at risk7–11. It is becoming clearer that a more 
sophisticated risk-based strategy, taking emphysema into account, for example, 
may be better than the current NLST criteria7,12–17  
The advantage of the LDCT based protocol is its simplicity and its high 
sensitivity. Refined criteria defining positive findings, largely based on nodule 
size and/or volume, reduce false positive rates. That notwithstanding, there is a 
need for evidence-based biomarkers to support pre- and post-test (LDCT) risk 
assessment18. Ideally, robust biomarkers would optimize image-based 
screening in two ways. First, they would allow further refinement of screening 
selection criteria, independent of age and tobacco exposure, in order to limit the 
costs of lung cancer screening. This risk management biomarker strategy would 
be a welcome addition to current screening practice. For example, a number of 
single nucleotide polymorphisms (SNPs) have been proposed in this regard as 
potential biomarkers of constitutive genomic risk for a given individual (see 
paragraph 4.4). Such biomarkers are the focus of ongoing research when 
integrated with current clinical-epidemiological risk models for lung cancer19. 
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Secondly, a validated panel of biomarkers may provide a post-test risk 
assessment capable of informing clinical decision making in the management of 
indeterminate pulmonary nodules (IPNs). Current management of IPNs is 
largely based on watchful waiting and may imply a risk of dissemination. 
Nodules found on annual screening, often so small that they are out of reach of 
current biopsy techniques, may benefit from a biomarker-based risk 
assessment. In particular biomarkers may be helpful in the case of patients with 
nodules that need sooner surveillance or a decision for biopsy. Patients with 
multiple nodules or those subject to frequent interval scans during screening 
might also benefit. Finally, biomarkers might also inform decisions regarding 
screening intervals, personalized follow up of survivors of screen detected early 
stage lung cancer, outcome prediction, or response to adjuvant therapy for 
those at high-risk of recurrence. In the present review we will refer only to the 
biomarkers intended for the first two unmet needs (risk management and IPN 
characterization). Other recent articles have dealt with early lung cancer 
prognostic biomarkers20,21. We will focus initially on biomarkers that are non-
invasive, reproducible and validated, and conclude the current review with other 
promising technologies which are being developed in the context of early 
detection.   
 
2. WHAT IS A GOOD BIOMARKER?  
The National Institutes of Health define a biomarker as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention”22. A useful biomarker must influence clinical decision making in a 
manner that leads to improved patient care. The benefit of clinical decisions 
based on true test results must outweigh the harms of decisions based on false 
positives or negatives. In the risk management setting, a biomarker should 
minimize harm and expense without leading to an increase in lung cancer 
deaths. When used for IPN characterization, a biomarker should anticipate the 
diagnosis of malignancy without substantially increasing the number of 
diagnostic procedures performed for benign nodules or delaying therapeutic 
procedures for malignant nodules23. 
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2.1 Optimizing lung cancer biomarker discovery 
We believe that validation of a clinically useful biomarker should adhere to the 
following principles summarized in table 1. Study design. Much is gained from 
the careful selection of the molecular approach chosen and should be guided by 
the intended use, where the biomarker would find potential clinical utility24. All 
too often investigators focus on versatility, seeking biomarkers which address 
multiple clinical needs such as risk assessment, diagnosis, or response to 
therapy. Much merit lies in limiting scope by addressing specific clinical needs. 
Biomarker stability. Information about the stability of the analyte over time, 
including changes in temperature, pH, enzymatic or oxidative stress is critical25. 
Analytical validation. Biomarker measurements should follow a well-defined 
strategy, and be accurate, precise and robust. Validation should include testing 
reproducibility against larger sources of variability such as biospecimen 
collection (e.g., sample processing, freeze thaw cycles, duration of storage, 
etc.), operator characteristics, laboratory environment, and quality control 
(standard curves, SOPs). Some variability is inherent to the technology itself 
(energy source, enzymatic activity, temperature control)26. Metrics of success 
include coefficient of variance, Z statistic, limits of detection, and quantitation. 
Clinical validation. The ideal diagnostic biomarker is both sensitive and 
specific, with diagnostic likelihood ratios independent of known predictors of the 
disease (e.g. age, smoking history or COPD). Validation should be performed in 
the clinical context of intended use. Case control studies are discouraged while 
prospective cohort studies and observational registries are preferable. The 
biomarker will be tested in multiple cohorts with similar prevalence of disease. 
Biomarkers rarely perform well across a large range of disease prevalence and 
their performance characteristics are often susceptible to changes in simple 
variables such as age or disease stage. Clinical utility. The biomarker should 
be tested for clinical utility in larger studies in a pragmatic setting, not disrupting 
the clinical workflow. The goal of any biomarker is to achieve superior 
performance compared to standard of care approaches and eventually reduce 
cost and harm of testing while limiting false negative rates23. Study design is 
challenging due to randomization and the need to impact clinical management 
(see below a potential trial design). Ultimately, implementation of the biomarker 
in routine practice will determine its true value for clinical decision making.  
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2.2. The metrics of success 
Biomarker performance and accuracy are dependent on the intended use and 
current alternatives. A successful biomarker must supersede the current 
standard of care27,28, be cost effective, welcomed by the community, and 
eventually demonstrate cancer control if early detection is the goal (Figure 1), or 
promote personalized medicine by identifying candidates for targeted 
therapies1. Understanding traditional metrics of success in this context is key. 
Sensitivity and specificity, for example, are often unstable over multiple 
variables such as age or disease stage. Positive and negative predictive values 
(PPV and NPV) are dependent on the prevalence of disease. ROC curves, i.e. 
true-positive vs false-positive rates (TPR and FPR), are helpful, but complicate 
decision making because of the need for dichotomous biomarker cut-off values. 
Reclassification indices have a role in testing a biomarker’s ability to accurately 
reclassify cases and controls and therefore influence clinical decision making.   
 
3. CURRENT PROMISING MOLECULAR BIOMARKERS 
3.1 Molecular biomarkers for lung cancer screening 
Blood is an obvious first choice as the source of biomarker candidates for lung 
cancer screening. Blood-based biomarkers provide an overview of the whole 
patient body, including the primary tumor, metastatic disease, immune 
response, and peri-tumoral stroma. However, sputum, bronchial lavage or 
aspirate samples, exhaled breath, or airway epithelium sampling are unique to 
lung and other respiratory tract cancers as potential sources of alternative 
biomarkers. These may provide information regarding molecular changes which 
may be anatomically closer to the tumor cells and their microenvironment and 
therefore potentially more relevant to clinical decision making in screened 
patients with early stage disease (Figure 2). Urine or saliva have also been 
collected as potential sources of biomarkers. The former is particularly useful in 
a metabolomics-based approach. 
A concise review of the most prominent molecular biomarkers for lung cancer 
screening includes examples of molecular candidates for both risk management 
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and IPN characterization in diverse stages of validation. We have included 
those which we consider most promising. We are well aware of the risk of 
omitting potential candidates. Table 2 includes a list of biomarkers which have 
reached different levels of validation. 
3.1.1. Autoantibodies 
Autoantibodies (AAbs) develop in response to an abnormal tumor antigen in 
some patients with lung cancer, often in the pre-clinical phase well before 
symptoms appear or imaging-based detection is possible. Autoantibodies have 
been identified in all histologic types and stages of lung cancer. They are 
usually absent or found in low titers in those without cancer, but also in many 
patients with the disease. Autoantibody panels are therefore likely to be specific 
but not sensitive. A well validated autoantibody panel has been studied in 
different screening cohorts as a lung cancer risk management approach29–36. In 
a clinical validation study including all lung cancer histologies and stages the 
panel performed well with 93% specificity, but only 40% sensitivity37. Similarly, a 
practice audit of 1699 patients (61 with lung cancer and 1/3 in stage I) found 
that the panel had robust specificity (91%) but low sensitivity (37%)33. 
Autoantibodies may find a place in clinical practice by improving the overall test 
accuracy of hybrid panels featuring diverse biomarkers38. 
 
3.1.2 Complement fragments  
Lung cancer can activate the complement cascade via the classical 
complement pathway39. Concentrations of a downstream split product of this 
pathway, C4d, are increased in biological fluids from lung cancer patients. 
Plasma C4d levels have been linked to increased lung cancer risk in a cohort of 
190 asymptomatic individuals, including 32 patients with screening detected 
cancer, enrolled in the iELCAP cohort (odds ratio = 4.38; 95% CI = 1.61 to 
11.93). In that study, potential confounders such as emphysema and COPD did 
not appear to affect C4d plasma levels39. Unfortunately, its use as a marker for 
the selection of risk patients could not be validated using samples from the 
MILD CT-screening trial40. Nevertheless, results on its use for the management 
of indeterminate pulmonary nodules are more promising. Plasma samples from 
patients from two independent cohorts with malignant nodules, presented 
8 
 
significantly higher levels of C4d than those with benign nodules. In selected 
patients with intermediate-sized pulmonary nodules (8-30 mm), C4d plasma 
levels identified benign lung nodules with an 84% NPV and a 54% PPV. Once 
again the test enjoyed high specificity (89%), at the expense of low sensitivity 
(44%)40. 
 
3.1.3 miRNAs  
Circulating microRNAs (miRNAs) reflecting tumor-host interactions, have 
emerged as potential biomarkers for cancer diagnosis and prognosis 
irrespective of tumor stage and mutational bourden36 (Verri et al, JTO 2017). 
The role of miRNA-based liquid biopsies has been assessed in the context of 
screening with LDCT in two large Italian retrospective validation studies37,38. 
Use of the miRNA signature classifier (MSC) and the miR-Test resulted in a 
five- and four-fold reduction in the LDCT-false positive rate with comparable 
specificity (81-75%) and sensitivity (87-78%). In post-surgical plasma samples, 
the MSC showed good performance in monitoring disease relapse (Sestini et al. 
Oncotarget 2015). The two tests are now undergoing prospective validation in 
three independent screening trials enrolling a total of 16,000 high-risk subjects.  
3.1.4 Circulating tumor DNA 
The value of circulating tumor DNA (ctDNA) as a biomarker in advanced tumor 
stages is well established41,42. However, its role in early lung cancer detection is 
still uncertain43. Abbosh et al. reported 48% sensitivity overall, setting a 
threshold of 2 single-nucleotide variants (SNVs) in 96 stage I-III NSCLC 
patients. Sensitivity ranged from 15% for stage I adenocarcinomas to 100% for 
stage II-III squamous cell carcinomas44. Current efforts to develop Next 
Generation Sequencing (NGS) technologies in order to study ctDNA in the 
context of early detection may improve sensitivity in this context (see below). 
 
3.1.5 Serum DNA methylation 
Tumor tissue is characterized by a global DNA hypomethylation status together 
with hypermethylation of specific CpG islands in the promoter region of tumor-
suppressor genes45. Hypermethylation of at least one of four studied genes was 
detected twenty years ago in 15 of 22 (68%) NSCLC tumors but not in any 
paired normal lung tissue. In these primary tumors with methylation, 11 of 15 
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(73%) samples also had abnormal methylated DNA in the matched serum 
sample46. More recently, a 64-qPCR-assay was studied in 204 serum samples 
from 33 lung cancer, 68 fibrotic ILD and 42 COPD patients, as well as 61 
healthy controls. The test had 88% sensitivity, 90% specificity when compared 
to controls, and 88% specificity when compared to COPD and ILD patients47. In 
2017, Ooki et al. reported that a 6-gene panel correctly classified 43 stage IA 
and 42 control subjects with 72% sensitivity and 71% specificity48. Hulbert et al. 
recently described a three-gene model discriminating subjects with suspicious 
nodules on CT imaging (150 stages I-II NSCLC and 60 controls) with 98% 
sensitivity and 71% specificity in sputum and 93% sensitivity and 62% 
specificity in plasma samples49.  
 
3.1.6 Serum protein profiling 
Many studies have identified measurable serum antigens in lung cancer 
patients. Panels of serum cancer antigens have been developed to improve 
diagnostic accuracy. One panel of 3 serum proteins (CEA, CA-125, CYFRA 21-
1) and an AAb (NY-ESO-1) performed well in a high-risk cohort with 71% 
sensitivity and 88% specificity for lung cancer38. Clinical validation was 
performed in a separate high-risk cohort (based on age and smoking history) 
with lower sensitivity (49%) but higher specificity (96%). The incorporation of 
clinical variables improved accuracy50. A different panel of cancer antigens 
(CEA, CA15.3, SCC, CYFRA 21-1, NSE, ProGRP) increased the AUC of a 
clinical prediction model based on nodule size, age, and smoking status from 
0.85 to 0.93 in a series of 3144 symptomatic individuals, including 1828 with 
lung cancer (52% stage IV) (Molina et al 2016). A two-protein biomarker ratio 
combined with a lung nodule clinical risk predictor had a sensitivity of 97% and 
a specificity of 44% for malignant disease in a series of 178 patients with 
suspicious lung nodules. This integrated classifier could have led to a 40% 
relative reduction in invasive testing for patients with benign nodules (10% 
ARR) while potentially delaying the management of 3% of malignant 
nodules50,51. 
 
3.1.7 RNA airway and nasal signature 
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Based on the “field of injury” paradigm52, airway epithelial gene-expression has 
been developed as a diagnostic biomarker for lung cancer. Initial studies 
focused on bronchial airway epithelial cells obtained via endobronchial 
brushings of the mainstem bronchus53,54. A 23-gene biomarker measured in 
bronchial epithelial cells has been tested as an adjuvant diagnostic biomarker 
for patients undergoing bronchoscopy for suspected lung cancer55. This 
biomarker underwent clinical validation in 2 independent prospective cohorts, 
demonstrating a sensitivity of 88-89% and a specificity of 48%. The biomarker 
was particularly helpful in patients with an intermediate (10-60%) pre-test risk of 
lung cancer (91% NPV). Patients with inconclusive bronchoscopy results could 
have benefited from the biomarker’s negative predictive value by avoiding 
further invasive testing, suggesting they could be followed safely with serial 
imaging studies28. Following analytic validation56 and other clinical studies57,58, 
the test received a favourable Medicare coverage decision in 2017. 
 
The same “field of injury” concept may be useful in samples of nasal epithelial 
cells. This approach has obvious advantages as a minimally invasive diagnostic 
alternative for those not undergoing bronchoscopy as part of their clinical work 
up. A 30-gene nasal expression panel has been developed for diagnosing lung 
cancer among ever smokers with suspected disease, demonstrating 
improvement in AUC, sensitivity, and NPV when combined with clinical risk 
models59.  
 
3.2 Current trials in which biomarkers are considered or included. 
Clinical validation study results have been published for a handful of 
biomarkers. Other biomarkers linger at various stages of development, while a 
few have entered formal clinical testing. The aforementioned panel of 
autoantibodies29 is currently being assessed as part of a Scottish NHS funded 
randomized controlled screening study enrolling 12,000 subjects (the ECLS 
study; NCT01925625). A bronchial gene-expression classifier that could 
improve the diagnostic performance of bronchoscopy is being tested in a large 
registry. The combination of the plasma MSC with LDCT results informs 
screening intervals in 4119 at risk subjects in the bioMILD screening trial 
(NCT02247453)60. Plasma samples prospectively collected during the 
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COSMOS II screening trial have been profiled to set-up and validate the clinical 
utility of the miR-Test (Lococo F et al, Lung 2015).  The DECAMP-1 and -2 
prospective observational trials (NCT01785342 and NCT02504697) have been 
designed to examine a variety of existing biomarkers for lung cancer diagnosis 
as well as new biomarkers discovered specifically in this clinical setting. 
DECAMP-1 seeks to improve follow-up of patients with IPNs by determining 
whether analyzed biomarkers are able to distinguish incidentally detected 
malignant from benign pulmonary nodules in high-risk smokers, while 
DECAMP-2 will test biomarkers of risk in asymptomatic high-risk screened 
individuals.  
 
An exciting amount of high-quality discovery and clinical validation work is 
ongoing. Some companies are in the process of planning true clinical utility 
studies for lung nodule management. The lack of an established trade-off 
regarding the consequences of true and false biomarker results is a challenge 
that every biomarker developer will face. It would behoove the clinical 
community to provide guidance regarding acceptable trade-offs both in the 
screening and the lung nodule management settings23. 
 
4. EMERGING BIOMARKERS, NEW TECHNOLOGIES TO FOLLOW AND 
FUTURE DIRECTIONS. THE POWER OF INTEGRATION 
The aforementioned biomarkers have been the object of intense research and a 
number of them are being assessed in a risk management strategy to 
recommend screening or aiming to characterize IPNs. We will now discuss 
promising new technologies with potential, including integrated approaches to 
biomarker development in lung cancer screening.  
 
4.1 Exhaled breath biomarkers 
There is growing evidence to support the use of exhaled breath (EB), including 
exhaled breath condensate (EBC) for diagnostic purposes, including cancer 
detection. The EBC, which includes cells and DNA fragments, may even 
support detection of resistant clones of EGFR cells61. The volatile fragments of 
the EB are sensitive biomarkers of lung cancer. Volatile organic compounds 
(VOCs) can be captured and analysed by a wide range of technologies, 
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including GC-MS, nano-sensors, colorimetric sensors, and other methods.62,63 
An artificially intelligent nano-array sensor has been used in the diagnosis and 
classification of 17 different diseases from breath samples of 1404 subjects, 
with 86% accuracy. Some studies suggest that such an array may discriminate 
benign from malignant pulmonary nodules64, or predict response to therapy and  
recurrence65. It may also distinguish histologic type66 or predict molecular 
analysis results67. Interestingly, it apparently may also discriminate between 
different types of cancer (lung, breast, colorectal, and prostate)68. 
 
4.2 Sputum cell based image analysis 
While sputum cytology has traditionally failed to yield either adequate or useful 
samples for lung cancer screening, the advent of “enhanced cytology”, in which 
sophisticated image analysis algorithms are combined with artificial intelligence, 
may yet prove sputum useful in this context. A newly developed test can identify 
abnormal cells in sputum samples of screened patients69. This test may be used 
as a primary screening modality with a reported sensitivity of 90% when 800 or 
more bronchial cells are available for analysis, or integrated with LDCT in the 
context of a conventional CT based screening program for IPN 
characterization70. In the latter case, fewer cells may be needed, since the 
clinician can integrate clinical, molecular or conventional sputum cytology data 
together with imaging results for greater diagnostic accuracy. 
 
4.3 Metabolomics 
A range of different analytical platforms and methodologies have been applied 
to identify metabolic biomarkers of lung cancer71. Metabolomics provides a 
direct functional readout of the phenotypic changes associated with the 
development of lung tumors and their microenvironment. Metabolomics has 
several advantages when compared to other omics, including a reduced 
number of metabolites and a wide range of biological samples that can be 
tested. Changes in lung cancer metabolites include those involved in glycolysis, 
the citric acid cycle, amino acid metabolism and cell membrane synthesis71,72. 
Metabolomics can differentiate between histological subtypes or genetic 
backgrounds73,74. A panel of metabolites excreted in the urine, including 
creatine riboside (CR) and N-acetylneuraminic acid (NANA), have been 
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associated with lung cancer risk prior to clinically detectable disease75,76. Panels 
as well as individual markers in blood, sputum, or exhaled breath condensate 
have also been proposed to identify high-risk candidates for screening or to 
discriminate between benign and malignant IPNs77–82. Finally, other -omics, 
such as microbiomics, are providing us with novel diagnostic markers that merit 
a closer look83 . 
 
4.4 Genetic predisposition to lung cancer 
The advent of GWAS analysis potentially could provide the lung cancer 
community with strong evidence of genetic susceptibility genes, which may be 
included in lung cancer risk prediction models12,13,84. Current evidence from a 
major review in 2017 of over 1000 candidate association studies, identified 22 
variants in 21 genes, which had strong cumulative epidemiological evidence of 
significant associations with lung cancer risk14.The OncoArray consortium 
research programme19 has provided recent new insights and a new set of 
susceptibility genes85, however, it still needs to be demonstrated that they make 
a significant contribution to risk prediction models used in lung cancer screening 
trials, over and above the patient’s epidemiological and clinical information86. 
However, these susceptibility genes do provide an insight into the biological 
process and association with specific pathologies, which are relevant to lung 
cancer aetiology87,88. The question which has to be asked, is how should we 
utilize the state of art mathematical and statistical approaches which can 
incorporate very large numbers of SNPs within risk models, through artificial 
intelligence and supervised machine learning approaches.  Clearly there is a 
wealth of information captured within the current GWAS data sets. We just need 
to find the next generation of tools to release it89,90. 
 
 
4.5 Integrating molecular biomarkers with radiomics and artificial 
intelligence 
The current scientific field of radiomics, a term first used by Dutch researcher 
Philippe Lambin in 2012, is a newcomer in search of biomarkers among the 
seemingly limitless supply of data related to lung cancer imaging based 
phenotypes and tumor microenvironment91,92. The accumulation of detailed 
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imaging data in the current era of artificial intelligence has set the stage for 
much progress in this field. Deep-learning architectures, for example, can be 
useful in lung nodule characterization93,94. Current research in the field is 
centered on robust identification of the region of interest in time, direct spatio-
temporal phenotypic characterization of tumor microenvironments, the 
integration of multiscale information at the local (nodule), regional (lobe), and 
organ levels, as well as the integration of imaging, clinical and -omics data in 
end to end learning architectures. 
 
The combination of imaging based deep learning with molecular biomarkers 
may be very powerful in the characterization of IPNs. Radiomics can identify 
EGFR and KRAS mutated tumors95,96. Imaging signatures based of quantitative 
analysis of imaging data can also predict survival97. Some studies have shown 
that the integration of plasma biomarkers and radiological characteristics is a 
better predictor of lung cancer in patients with IPNs98. Prediction models 
integrating serum biomarkers with clinical characteristics and radiographic 
features of suspicious nodules correctly identified malignant nodules in several 
studies27,99. The integrated models outperform the use of serum biomarkers 
alone and overall represent a very promising approach for the future of early 
lung cancer detection, especially if artificial intelligence is incorporated100–102. 
 
4.6 Integration of multiple next generation sequencing (NGS) analysis in 
circulating DNA.  
We have already alluded to the use of NGS of ctDNA as a promising strategy 
for early lung cancer detection. The biggest technical challenge is sensitivity. In 
an attempt to overcome this limitation, a recently reported test for pan-cancer 
early detection combined the NGS analysis of ctDNA in blood with a large panel 
of protein biomarkers in 1,005 stage I-III pan-cancer patients and 812 cancer-
free controls103. While specificity was > 99%, sensitivity ranged from 33% for 
breast cancer to 98% for ovarian cancer. The sensitivity for lung cancer was 
59% in 104 patients. Although promising, the study had some important 
limitations including the fact that most cancer patients were symptomatic, and 
control subjects had no comorbidities which could have acted as confounding 
variables. 
15 
 
 
The scientific community is also awaiting results of the Circulating Cell-free 
Genome Atlas Study (CCGA) for early cancer detection, enrolling 15,000 
participants including cancer-free controls in the U.S. and Canada. Plasma 
samples collected at baseline and during 5 years of follow-up will be analyzed 
by whole-genome sequencing (WGS) for copy number variation (CNV), 
targeted DNA sequencing (507-gene panel), and whole genome methylome 
profiling. Preliminary results in an observational case-control setting include 
95% specificity, high sensitivity for advanced lung cancer in 54 patients (85% 
for targeted sequencing, 91% for CNV WGS, and 93% for methylome profiling), 
and modest sensitivity for 63 patients with stage I-III lung cancer (48% for 
targeted NGS, 54% for CNV WGS, and 56% for methylome profiling)104. The 
generalizability of these findings to the screening setting is uncertain. A recent 
review by Aravanis, Lee and Klausner105 addressed the challenges NGS faces 
in early cancer detection. The authors suggested that a successful pan-cancer 
screening NGS-based blood test would have to test up to 1000 genes, and the 
ctDNA limit of detection (sensitivity) would have to improve ten-fold from the 
current 0.1% to less than 0.01%. More importantly, a validation trial would have 
to enroll between 10,000 and 100,000 individuals. Despite these seemingly long 
odds, an observational trial (NCT02889978) investigating the discriminating 
power of the CCGA test is already under way. 
 
5. FUTURE RESEARCH CHALLENGES  
 
Table 3 summarizes the research challenges faced by biomarker development 
in the context of lung cancer screening. The interaction between genetics and 
environment is multidimensional and hard to control. Samples need to be 
carefully collected, processed using standard operating procedures, and 
annotated using clinical variables reliably collected from patients and/or 
electronic medical records106. Informed consent is essential to preserve 
confidentiality (CoC). Researchers with a CoC may only disclose identifiable, 
sensitive information if the subject consents, while anyone conducting research 
as a sub-awardee or receiving a copy of identifiable sensitive information must 
also comply with and understand disclosure restrictions. Even though samples 
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may be anonymized, genetic fingerprints may reveal a subject’s identity 
rendering us vulnerable to the misuse of our most personal information. On the 
other hand, genetic privacy acts can hinder progress in this field107.  
 
Because so many biomarkers are approaching clinical validation, the field is in 
great need of standardized metrics of clinical utility. In the context of lung 
cancer screening, we can envision a study design (Figure 3) that would test the 
clinical utility of a biomarker-based risk assessment strategy. Because many 
patients with lung cancer do not meet NLST screening criteria, the study would 
test the value of a candidate biomarker as a predictor of risk independent of age 
and tobacco exposure and therefore justify annual screening with LDCT for 5 
years (the duration of the trial). Conceivably, patients not meeting the U.S. 
Preventive Services Task Force (USPSTF) or other formally accepted 
screening criteria could be prospectively enrolled based on modeling outcomes. 
Indeed, the selection criteria could also include those used in other settings, 
such as the PanCAN and UKLS, with used risk-based prediction models19,85. 
The study would perform biomarker testing using a clinically validated 
biomarker(s) and assign patients to management strategies based on the 
results of combined testing.  Those identified by the biomarker as having a lung 
cancer risk akin to those meeting USPSTF, PLCO2012, LLPv2, or other 
accepted criteria would be offered LDCT. Those identified as having a lower risk 
profile would be followed without LDCT. All subjects would sign an informed 
consent and undergo biomarker testing (or a series of tests). The primary 
outcome of this hypothetical trial would be risk prediction accuracy. Nodule 
management would follow current clinical guidelines. Biomarker test results 
would be shared with the patient and his/her provider, who would in turn decide 
in light of the results whether LDCT is warranted or not.  We would recommend 
testing patient-reported outcomes based on expected risks and benefits of 
getting tested, the way the test results are communicated, anxiety related to test 
results, smoking habits, and willingness to undergo further testing based on 
biomarker results. We would also recommend determining the accuracy of the 
risk assessment before and after biomarker testing as well as outcome values. 
The best sequence (annual vs biannual) and combination of tests to offer 
should also be tested.  Such a study would pave the way for a biomarker of risk 
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driven strategy for lung cancer screening. An alternative trial designed to 
validate the clinical utility of diagnostic biomarkers in the context of IPNs found 
incidentally could also be undertaken.  
 
6. THE FUTURE OF MOLECULAR BIOMARKERS IN THE CONTEXT OF 
LUNG CANCER SCREENING 
Despite the vast potential of existing candidates and methodologies, no single 
lung cancer molecular biomarker is currently being used in routine clinical 
practice. The clinical validation and utility steps are critical, but much more 
demanding, resource needy, and time consuming than the initial discovery and 
retrospective validation. That notwithstanding, the unmet clinical needs remain. 
Individual risk needs to be refined, and screening criteria modified in order to 
impact lung cancer related mortality. Orphan images of IPNs stand to improve 
our success differentiating benign from malignant with a robust biomarker at our 
disposal. There is also a clear unmet need for prognostic molecular and clinical 
markers for patients with screening detected early stage tumors. Although some 
believe that testing a new biomarker would be comparable to the gargantuan 
effort embodied by the NLST, we believe that less complex and more affordable 
validation is possible in the setting of established lung cancer screening 
programs.  
There is plenty of room for improvement. We need to promote studies 
integrating promising candidate biomarkers, including molecular and image-
based, and the use of artificial intelligence technologies to help in the selection 
of the most appropriate combinations. Head to head comparisons of biomarkers 
in specific clinical scenarios would also be welcome. Deep mining of the troves 
of data provided by ongoing screening efforts with new mathematical and 
computational models based on machine learning will surely help. This will 
require a systematic collection of patient samples in the context of screening. 
Finally, ways to prove cost-effectiveness of the new tests as well as to 
overcome the potential hurdles to get the approval by regulatory agencies need 
to be considered in the list of challenges that we face ahead in the development 
of molecular biomarkers in screening. Although the logistics and expense of 
such an effort may seem daunting at first, we believe the long-term outcome 
may prove highly efficient. 
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TABLES AND FIGURES 
 
Table 1: Principles to optimize the research on lung cancer 
biomarker development 
 
• Principle 1: Selection of the molecular approach guided by the intended 
use. 
• Principle 2:  Look for stable analytes, minimally dependent on storage 
time, temperature, pH, enzymatic or oxidative stress. 
• Principle 3: The analyte should be measured with accuracy, precision 
and robustness. Thoroughly test for reproducibility across sources of 
variability, laboratories, conditions, etc.  
• Principle 4: Test the biomarker in multiple cohorts in the clinical context 
it will be considered for use (screening, nodule management). Case 
control studies are discouraged, while prospective cohort studies and 
eventually observational registries are favored though less convenient.  
• Principle 5:  Tests in larger cohorts to demonstrate superiority over 
standard of care, reduction of cost and false positive and negative rates 
reduction 
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Table 2: Candidate biomarkers for lung cancer early detection and phase of development 
Candidates Biomarker Target Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 References Trial 
 Discovery, 
prediction 
Assay 
validation 
Retrolongitudinal Clinical 
validation*  
Clinical 
utility 
  
SERUM/PLASMA          
Specific 
proteins/autoantibodies 
Three proteins (CEA, CA-125, and CYFRA 21–1) and 
1 AAb (NY-ESO-1) 
RMS   38  
Two proteins (LG3BP and C163A) and clinical 
features 
DIPN   51 NCT01752114 
Seven AAbs (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, 
HuD, and MAGE A4) 
RMS    31,33 NCT01700257 
DIPN   36  
Six proteins (CEA, CA-125, CEA 15-3, SCC, CYFRA 
21–1, NSE, and proGRP) 
DIPN     109,110   
Complement fragment C4d RMS     39  
DIPN    40  
MiRNA Ratios among 24 miRNAs RMS    110,111 NCT02247453 
DIPN  
Signature of 13 microRNA + 6 for normalization RMS                           112 COSMOS II 
trial  DIPN     
Signature of 2 microRNA DIPN       113  
DNA methylation SOX2 and PTGER4 methylation RMS    114,115  
DIPN  
Circulating tumor nucleic 
acids 
Circulating tumor DNA; NGS technology RMS     104 NCT02889978 
 Circulating tumor DNA; NGS technology DIPN      116  
 Circulating tumor DNA; Ion Torrent DNA Sequencing 
technology 
DIPN      117  
 Circulating tumor DNA; TEC-Seq technology RMS      118  
 Signature of 29 genes (RNA) DIPN      119  
 ctDNA mutation and proteins (CA-125, CEA, CA19-9, 
PRL, HGF, OPN, MPO, and TIMP-1) 
DIPN      103  
TUMOR/AIRWAY EPITHELIUM  
Chromosome aberrations Chromosome regions copy number or fusions (FISH) DIPN      120  
mRNA gene expression 
classifier 
Twenty three gene classifier DIPN    NCT01309087 
NCT00746759 
SNPs 12 SNPs for COPD and clinical features RMS   100,121  
SPUTUM, BREATH AND 
URINE 
         
DNA methylation SHOX2 and RASSF1A methylation RMS    122  
MiRNA Signature of 3 microRNA DIPN     123  
Exhaled breath VOC- Nanoparticle Biometric Tagging (NBT) DIPN       
VOC- Field Asymmetric Ion Mobility Spectrometry 
(FAIMS) 
     NCT02612532 
Tumor cells >700 morphological features (by Cell CT) RMS       
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DIPN       
Buccal nanocytology RMS      124  
 Porphyrin differential uptake by tumor cells RMS     125  
Unrine markers Metabolites RMS      76  
RMS: risk management in screening context; DIPN: diagnosis of indeterminate pulmonary nodules; *DECAMP-1 and DECAMP-2 trials (NCT01785342 and NCT02504697) are currently recruiting 
patients in order to test some of these biomarkersAAB Autoantibody. 
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Figure 1. Metric for evaluation of clinical use of candidate biomarkers. Proposed 
metric for success is suggested for the level at or above the red arrows. From 
Atwater et al. Semin Respir Crit Care Med 2016;37:670–680. 
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Figure 2 Sources of biomarkers in lung cancer screening
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Fig 3 Potential design for testing the efficacy of a biomarker based test to 
optimize a LDCT lung cancer screening program  
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Table 3: Challenges faced by the research on lung cancer 
biomarker development 
•  
• Challenge 1: Need for deeper knowledge of lung carcinogenesis, tumor 
molecular and cellular landscape, gene-environment relationship, etc.  
• Challenge 2: Need for careful sample collection; processing using 
standard operating procedures and properly annotated clinical data in the 
intended use type of patient (screening cohorts). 
• Challenge 3:  Need to obtain the samples from individuals following 
informed consent and comply with all rules, regulations and policies 
regarding human subjects’ research. 
• Challenge 4: Need to establish robust consensus criteria for the 
selection of the single or integrated combined biomarkers to be tested  
• Challenge 5: Need to design and approve new mechanisms to show clinical 
utility of care, reduction of cost,  false positive/negative rates reduction 
and aceptable ratios of true and false results. 
• Challenge 6: Need to further convince stakeholders and research 
promoters and funders of the relevance of developing single and 
integrated biomarkers to optimize the efficacy of current lung cancer 
screening protocols.  
• Challenge 7: Need to analyze, determine the causes and try to 
overcome potentially unnecessary hurdles to approval even after utility 
testing is complete.   
 
 
 
Commented [MMP1]: There may be hurdles to approval even 
after utility testing is complete. 
Commented [LM2]: Please look at this new challenge to answer 
Peter Mazzones previous comment. 
